Biosimilar Testing Service - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB510241141

Publication Date:

October 31, 2024

Pages:

109

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Biosimilar are the biological based products used for various use in healthcare industry. Biosimilar products are very helpful to the patients and also offer therapeutic options. Biosimilar have a unique properties, which is used to study the biological functions and structures complexity of the sample.
The global market for Biosimilar Testing Service was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Biosimilar Testing Service, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Biosimilar Testing Service by region & country, by Type, and by Application.
The Biosimilar Testing Service market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilar Testing Service.
Market Segmentation
By Company
Charles River Laboratories International
Merck
PPD
LAB Holdings
Eurofins Scientific
Intertek
SGS
Profacgen
Antibody Analytics
Kymos Pharma Services
Medicilon
Pacific BioLabs
Sartorius
Segment by Type:
Pharmacokinetic Assay
Tiered Immunogenicity Testing
Others
Segment by Application
Hospitals
Pharmaceutical Companies
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Biosimilar Testing Service manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Biosimilar Testing Service in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Biosimilar Testing Service in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Market Overview
1.1 Biosimilar Testing Service Product Introduction
1.2 Global Biosimilar Testing Service Market Size Forecast
1.3 Biosimilar Testing Service Market Trends & Drivers
1.3.1 Biosimilar Testing Service Industry Trends
1.3.2 Biosimilar Testing Service Market Drivers & Opportunity
1.3.3 Biosimilar Testing Service Market Challenges
1.3.4 Biosimilar Testing Service Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Biosimilar Testing Service Players Revenue Ranking (2023)
2.2 Global Biosimilar Testing Service Revenue by Company (2019-2024)
2.3 Key Companies Biosimilar Testing Service Manufacturing Base Distribution and Headquarters
2.4 Key Companies Biosimilar Testing Service Product Offered
2.5 Key Companies Time to Begin Mass Production of Biosimilar Testing Service
2.6 Biosimilar Testing Service Market Competitive Analysis
2.6.1 Biosimilar Testing Service Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Biosimilar Testing Service Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilar Testing Service as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Pharmacokinetic Assay
3.1.2 Tiered Immunogenicity Testing
3.1.3 Others
3.2 Global Biosimilar Testing Service Sales Value by Type
3.2.1 Global Biosimilar Testing Service Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Biosimilar Testing Service Sales Value, by Type (2019-2030)
3.2.3 Global Biosimilar Testing Service Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals
4.1.2 Pharmaceutical Companies
4.1.3 Others
4.2 Global Biosimilar Testing Service Sales Value by Application
4.2.1 Global Biosimilar Testing Service Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Biosimilar Testing Service Sales Value, by Application (2019-2030)
4.2.3 Global Biosimilar Testing Service Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Biosimilar Testing Service Sales Value by Region
5.1.1 Global Biosimilar Testing Service Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Biosimilar Testing Service Sales Value by Region (2019-2024)
5.1.3 Global Biosimilar Testing Service Sales Value by Region (2025-2030)
5.1.4 Global Biosimilar Testing Service Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Biosimilar Testing Service Sales Value, 2019-2030
5.2.2 North America Biosimilar Testing Service Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Biosimilar Testing Service Sales Value, 2019-2030
5.3.2 Europe Biosimilar Testing Service Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Biosimilar Testing Service Sales Value, 2019-2030
5.4.2 Asia Pacific Biosimilar Testing Service Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Biosimilar Testing Service Sales Value, 2019-2030
5.5.2 South America Biosimilar Testing Service Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Biosimilar Testing Service Sales Value, 2019-2030
5.6.2 Middle East & Africa Biosimilar Testing Service Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Biosimilar Testing Service Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Biosimilar Testing Service Sales Value
6.3 United States
6.3.1 United States Biosimilar Testing Service Sales Value, 2019-2030
6.3.2 United States Biosimilar Testing Service Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Biosimilar Testing Service Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Biosimilar Testing Service Sales Value, 2019-2030
6.4.2 Europe Biosimilar Testing Service Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Biosimilar Testing Service Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Biosimilar Testing Service Sales Value, 2019-2030
6.5.2 China Biosimilar Testing Service Sales Value by Type (%), 2023 VS 2030
6.5.3 China Biosimilar Testing Service Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Biosimilar Testing Service Sales Value, 2019-2030
6.6.2 Japan Biosimilar Testing Service Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Biosimilar Testing Service Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Biosimilar Testing Service Sales Value, 2019-2030
6.7.2 South Korea Biosimilar Testing Service Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Biosimilar Testing Service Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Biosimilar Testing Service Sales Value, 2019-2030
6.8.2 Southeast Asia Biosimilar Testing Service Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Biosimilar Testing Service Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Biosimilar Testing Service Sales Value, 2019-2030
6.9.2 India Biosimilar Testing Service Sales Value by Type (%), 2023 VS 2030
6.9.3 India Biosimilar Testing Service Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Charles River Laboratories International
7.1.1 Charles River Laboratories International Profile
7.1.2 Charles River Laboratories International Main Business
7.1.3 Charles River Laboratories International Biosimilar Testing Service Products, Services and Solutions
7.1.4 Charles River Laboratories International Biosimilar Testing Service Revenue (US$ Million) & (2019-2024)
7.1.5 Charles River Laboratories International Recent Developments
7.2 Merck
7.2.1 Merck Profile
7.2.2 Merck Main Business
7.2.3 Merck Biosimilar Testing Service Products, Services and Solutions
7.2.4 Merck Biosimilar Testing Service Revenue (US$ Million) & (2019-2024)
7.2.5 Merck Recent Developments
7.3 PPD
7.3.1 PPD Profile
7.3.2 PPD Main Business
7.3.3 PPD Biosimilar Testing Service Products, Services and Solutions
7.3.4 PPD Biosimilar Testing Service Revenue (US$ Million) & (2019-2024)
7.3.5 LAB Holdings Recent Developments
7.4 LAB Holdings
7.4.1 LAB Holdings Profile
7.4.2 LAB Holdings Main Business
7.4.3 LAB Holdings Biosimilar Testing Service Products, Services and Solutions
7.4.4 LAB Holdings Biosimilar Testing Service Revenue (US$ Million) & (2019-2024)
7.4.5 LAB Holdings Recent Developments
7.5 Eurofins Scientific
7.5.1 Eurofins Scientific Profile
7.5.2 Eurofins Scientific Main Business
7.5.3 Eurofins Scientific Biosimilar Testing Service Products, Services and Solutions
7.5.4 Eurofins Scientific Biosimilar Testing Service Revenue (US$ Million) & (2019-2024)
7.5.5 Eurofins Scientific Recent Developments
7.6 Intertek
7.6.1 Intertek Profile
7.6.2 Intertek Main Business
7.6.3 Intertek Biosimilar Testing Service Products, Services and Solutions
7.6.4 Intertek Biosimilar Testing Service Revenue (US$ Million) & (2019-2024)
7.6.5 Intertek Recent Developments
7.7 SGS
7.7.1 SGS Profile
7.7.2 SGS Main Business
7.7.3 SGS Biosimilar Testing Service Products, Services and Solutions
7.7.4 SGS Biosimilar Testing Service Revenue (US$ Million) & (2019-2024)
7.7.5 SGS Recent Developments
7.8 Profacgen
7.8.1 Profacgen Profile
7.8.2 Profacgen Main Business
7.8.3 Profacgen Biosimilar Testing Service Products, Services and Solutions
7.8.4 Profacgen Biosimilar Testing Service Revenue (US$ Million) & (2019-2024)
7.8.5 Profacgen Recent Developments
7.9 Antibody Analytics
7.9.1 Antibody Analytics Profile
7.9.2 Antibody Analytics Main Business
7.9.3 Antibody Analytics Biosimilar Testing Service Products, Services and Solutions
7.9.4 Antibody Analytics Biosimilar Testing Service Revenue (US$ Million) & (2019-2024)
7.9.5 Antibody Analytics Recent Developments
7.10 Kymos Pharma Services
7.10.1 Kymos Pharma Services Profile
7.10.2 Kymos Pharma Services Main Business
7.10.3 Kymos Pharma Services Biosimilar Testing Service Products, Services and Solutions
7.10.4 Kymos Pharma Services Biosimilar Testing Service Revenue (US$ Million) & (2019-2024)
7.10.5 Kymos Pharma Services Recent Developments
7.11 Medicilon
7.11.1 Medicilon Profile
7.11.2 Medicilon Main Business
7.11.3 Medicilon Biosimilar Testing Service Products, Services and Solutions
7.11.4 Medicilon Biosimilar Testing Service Revenue (US$ Million) & (2019-2024)
7.11.5 Medicilon Recent Developments
7.12 Pacific BioLabs
7.12.1 Pacific BioLabs Profile
7.12.2 Pacific BioLabs Main Business
7.12.3 Pacific BioLabs Biosimilar Testing Service Products, Services and Solutions
7.12.4 Pacific BioLabs Biosimilar Testing Service Revenue (US$ Million) & (2019-2024)
7.12.5 Pacific BioLabs Recent Developments
7.13 Sartorius
7.13.1 Sartorius Profile
7.13.2 Sartorius Main Business
7.13.3 Sartorius Biosimilar Testing Service Products, Services and Solutions
7.13.4 Sartorius Biosimilar Testing Service Revenue (US$ Million) & (2019-2024)
7.13.5 Sartorius Recent Developments
8 Industry Chain Analysis
8.1 Biosimilar Testing Service Industrial Chain
8.2 Biosimilar Testing Service Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Biosimilar Testing Service Sales Model
8.5.2 Sales Channel
8.5.3 Biosimilar Testing Service Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Charles River Laboratories International
Merck
PPD
LAB Holdings
Eurofins Scientific
Intertek
SGS
Profacgen
Antibody Analytics
Kymos Pharma Services
Medicilon
Pacific BioLabs
Sartorius

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂